search
Back to results

Selenium for Prevention of Adenomatous Colorectal Polyps

Primary Purpose

Colorectal Cancer, Adenomatous Colorectal Polyps, Precancerous Condition

Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Selenium
Sponsored by
University of Arizona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Colorectal Cancer focused on measuring colon cancer, rectal cancer, colorectal cancer, adenomatous polyp

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

DISEASE CHARACTERISTICS: Histologically confirmed colorectal adenomatous polyps Meets the following criteria by colonoscopy (performed within the past 6 months): Cecum was totally visualized or reached At least 90% visualization of colon surface area Removed at least 1 adenomatous polyp of at least 3 mm in size during procedure (For the Advanced Adenoma Sub-study: Removal of at least 1 advanced colorectal adenomatous polyp during procedure. An adenoma is considered advanced if it is 10 mm or greater in size, and/or has villous histology and/or shows high grade dysplasia) Removed no more than 10 adenomatous polyps of any size by endoscopy All other neoplastic and non-neoplastic colon polyps must have been completely removed (except for diminutive [less than 3 mm] sessile rectal polyps) For the sub-study, at least 1 advanced adenomatous polyp defined as 10 mm or greater in size and/or has villous histology and/or shows high grade dysplasia No prior diagnosis of any of the following: Colorectal cancer Familial adenomatous polyposis Ulcerative colitis Crohn's disease Hereditary non-polyposis colon cancer (HNPCC), defined as: Histologically confirmed colorectal cancer in at least 3 relatives, 1 of whom is a first-degree relative of the other 2 Disease occurrence in at least 2 consecutive generations Colorectal cancer diagnosis in at least 1 family member who is less than 50 years of age Patients with a family history of colorectal cancer but who are not diagnosed with HNPCC are allowed No more than 1 prior segmental colon resection PATIENT CHARACTERISTICS: Age 40 to 80 Performance status SWOG 0-1 Life expectancy Not specified Hematopoietic Hemoglobin > 11 g/dL WBC 3,000 - 11,000/mm^3 Hepatic AST and ALT < 2 times upper limit of normal Bilirubin < 2.0 mg/dL Renal Creatinine < 1.9 mg/dL Cardiovascular No unstable* cardiac disease despite medication (e.g., diuretics or digitalis) No uncontrolled hypertension (i.e., systolic blood pressure ≥ 170 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg) despite medication NOTE: *Unstable defined as unable to walk across the room without chest pain or shortness of breath Other Not pregnant or nursing Fertile patients must use effective contraception for at least 2 months before and during study treatment Resident of a clinical center metropolitan area or obtaining regular health care in a clinical metropolitan area for at least 6 months out of the year Must be able to swallow pills No unexpected weight loss of 10% or more within the past 6 months No prior rheumatoid arthritis No poorly controlled diabetes mellitus despite medication, defined as: Blood sugar level ≥ 200 mg/dL on more than half of the readings taken within the past month No invasive malignancy within the past 5 years that required medical excision, radiotherapy, or chemotherapy except basal cell or squamous cell carcinoma PRIOR CONCURRENT THERAPY: Biologic therapy No concurrent drugs that regulate the immune system Chemotherapy No concurrent chemotherapy Endocrine therapy Not specified Radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Other Prior enrollment in another adenoma prevention study allowed Concurrent routine aspirin (≤ 81 mg/day) allowed No regular use of non-steroidal anti-inflammatory drugs (NSAIDs) No concurrent enrollment in another research study using pharmacological cancer drugs, a cyclo-oxygenase-2 inhibitor, or selenium No other concurrent selenium unless dosage is ≤ 50 µg/day

Sites / Locations

  • Veterans Affairs Medical Center - Phoenix
  • Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea
  • Mayo Clinic Scottsdale
  • Arizona Cancer Center - Tucson Clinic
  • University of Colorado Cancer Center at UC Health Sciences Center
  • Endoscopy Center of Western New York
  • Baylor University Medical Center - Dallas

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Selenium

Placebo

Arm Description

Participants receive oral selenium 200 mcg once daily.

Participants receive oral placebo once daily.

Outcomes

Primary Outcome Measures

Number of Recurrent Adenomas at Surveillance Colonoscopy
Detection of metachronous colorectal adenomas during follow-up, by treatment, in the original cohort. Surveillance colonoscopy is recommended 3 to 5 years after removal of colorectal adenoma(s). Participants will remain on the study intervention until their surveillance colonoscopy. Surveillance colonoscopy is determined by participants' GI physician.
Median Selenium Blood Levels at One Year.
Adequate adherence to long-term selenium treatment as measured by blood selenium levels (ng/mL) at one year.

Secondary Outcome Measures

Full Information

First Posted
March 8, 2004
Last Updated
September 3, 2019
Sponsor
University of Arizona
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00078897
Brief Title
Selenium for Prevention of Adenomatous Colorectal Polyps
Official Title
Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Terminated
Why Stopped
Concluded - Terminated by PI
Study Start Date
January 20, 2005 (Actual)
Primary Completion Date
January 7, 2014 (Actual)
Study Completion Date
May 17, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Arizona
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Selenium may be effective in preventing the recurrence of adenomatous colorectal polyps. PURPOSE: This randomized phase III trial is studying selenium to see how well it works in preventing the recurrence of polyps in patients with adenomatous colorectal polyps.
Detailed Description
OBJECTIVES: Primary Compare the effects of selenium vs placebo on the recurrence of adenomatous colorectal polyps, in terms of histologic type, degree of dysplasia, number, size, and location, in patients with adenomatous colorectal polyps. Compare the type, incidence, and outcome of side effects in patients treated with these regimens. Determine patient adherence to long-term treatment with these regimens. Secondary Determine the effects of regimen modification by baseline blood selenium level, low-dose aspirin, selenoprotein genetic marker polymorphisms (e.g., GPx-1, GPx-2, and SEP15) Determine the effects of low-dose aspirin (81 mg/day) modification by ornithine decarboxylase promoter genotype, and toxicity by slow-metabolizer genotypes of the cytochrome p450 2C9 and UT1A6 loci in these patients. OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to use of low-dose (≤ 81 mg/day) aspirin (yes vs no). Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive oral selenium once daily. Arm II: Patients receive oral placebo once daily. In both arms, treatment continues for up to 5 years* in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up colonoscopy approximately 5 years* after baseline colonoscopy. NOTE: Some patients will continue participation for up to 7 and a half years PROJECTED ACCRUAL: A total of 1,600 patients with an adenoma will be randomized to this study, followed by a second group of randomization of 200 patients with at least one advanced adenoma (at baseline) for a substudy. Total planned randomizations = 1,800 participants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Adenomatous Colorectal Polyps, Precancerous Condition
Keywords
colon cancer, rectal cancer, colorectal cancer, adenomatous polyp

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1621 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Selenium
Arm Type
Active Comparator
Arm Description
Participants receive oral selenium 200 mcg once daily.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants receive oral placebo once daily.
Intervention Type
Drug
Intervention Name(s)
Selenium
Other Intervention Name(s)
SelenoExcell
Intervention Description
Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
Primary Outcome Measure Information:
Title
Number of Recurrent Adenomas at Surveillance Colonoscopy
Description
Detection of metachronous colorectal adenomas during follow-up, by treatment, in the original cohort. Surveillance colonoscopy is recommended 3 to 5 years after removal of colorectal adenoma(s). Participants will remain on the study intervention until their surveillance colonoscopy. Surveillance colonoscopy is determined by participants' GI physician.
Time Frame
3 to 5 years after baseline colonoscopy
Title
Median Selenium Blood Levels at One Year.
Description
Adequate adherence to long-term selenium treatment as measured by blood selenium levels (ng/mL) at one year.
Time Frame
One year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed colorectal adenomatous polyps Meets the following criteria by colonoscopy (performed within the past 6 months): Cecum was totally visualized or reached At least 90% visualization of colon surface area Removed at least 1 adenomatous polyp of at least 3 mm in size during procedure (For the Advanced Adenoma Sub-study: Removal of at least 1 advanced colorectal adenomatous polyp during procedure. An adenoma is considered advanced if it is 10 mm or greater in size, and/or has villous histology and/or shows high grade dysplasia) Removed no more than 10 adenomatous polyps of any size by endoscopy All other neoplastic and non-neoplastic colon polyps must have been completely removed (except for diminutive [less than 3 mm] sessile rectal polyps) For the sub-study, at least 1 advanced adenomatous polyp defined as 10 mm or greater in size and/or has villous histology and/or shows high grade dysplasia No prior diagnosis of any of the following: Colorectal cancer Familial adenomatous polyposis Ulcerative colitis Crohn's disease Hereditary non-polyposis colon cancer (HNPCC), defined as: Histologically confirmed colorectal cancer in at least 3 relatives, 1 of whom is a first-degree relative of the other 2 Disease occurrence in at least 2 consecutive generations Colorectal cancer diagnosis in at least 1 family member who is less than 50 years of age Patients with a family history of colorectal cancer but who are not diagnosed with HNPCC are allowed No more than 1 prior segmental colon resection PATIENT CHARACTERISTICS: Age 40 to 80 Performance status SWOG 0-1 Life expectancy Not specified Hematopoietic Hemoglobin > 11 g/dL WBC 3,000 - 11,000/mm^3 Hepatic AST and ALT < 2 times upper limit of normal Bilirubin < 2.0 mg/dL Renal Creatinine < 1.9 mg/dL Cardiovascular No unstable* cardiac disease despite medication (e.g., diuretics or digitalis) No uncontrolled hypertension (i.e., systolic blood pressure ≥ 170 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg) despite medication NOTE: *Unstable defined as unable to walk across the room without chest pain or shortness of breath Other Not pregnant or nursing Fertile patients must use effective contraception for at least 2 months before and during study treatment Resident of a clinical center metropolitan area or obtaining regular health care in a clinical metropolitan area for at least 6 months out of the year Must be able to swallow pills No unexpected weight loss of 10% or more within the past 6 months No prior rheumatoid arthritis No poorly controlled diabetes mellitus despite medication, defined as: Blood sugar level ≥ 200 mg/dL on more than half of the readings taken within the past month No invasive malignancy within the past 5 years that required medical excision, radiotherapy, or chemotherapy except basal cell or squamous cell carcinoma PRIOR CONCURRENT THERAPY: Biologic therapy No concurrent drugs that regulate the immune system Chemotherapy No concurrent chemotherapy Endocrine therapy Not specified Radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Other Prior enrollment in another adenoma prevention study allowed Concurrent routine aspirin (≤ 81 mg/day) allowed No regular use of non-steroidal anti-inflammatory drugs (NSAIDs) No concurrent enrollment in another research study using pharmacological cancer drugs, a cyclo-oxygenase-2 inhibitor, or selenium No other concurrent selenium unless dosage is ≤ 50 µg/day
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
M. Peter Lance, MD
Organizational Affiliation
University of Arizona
Official's Role
Principal Investigator
Facility Information:
Facility Name
Veterans Affairs Medical Center - Phoenix
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85012
Country
United States
Facility Name
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85258-4512
Country
United States
Facility Name
Mayo Clinic Scottsdale
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85259-5499
Country
United States
Facility Name
Arizona Cancer Center - Tucson Clinic
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724-5024
Country
United States
Facility Name
University of Colorado Cancer Center at UC Health Sciences Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80220
Country
United States
Facility Name
Endoscopy Center of Western New York
City
Williamsville
State/Province
New York
ZIP/Postal Code
14221
Country
United States
Facility Name
Baylor University Medical Center - Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
35815403
Citation
Trejo MJ, Batai K, Chen Y, Brezina S, Chow HS, Ellis N, Lance P, Hsu CH, Pogreba-Brown K, Bishop M, Gsur A, Jacobs ET. Genome-Wide Association Study of Metachronous Colorectal Adenoma Risk among Participants in the Selenium Trial. Nutr Cancer. 2023;75(1):143-153. doi: 10.1080/01635581.2022.2096910. Epub 2022 Jul 9.
Results Reference
derived
PubMed Identifier
30899530
Citation
Jacobs ET, Lance P, Mandarino LJ, Ellis NA, Chow HS, Foote J, Martinez JA, Hsu CP, Batai K, Saboda K, Thompson PA. Selenium supplementation and insulin resistance in a randomized, clinical trial. BMJ Open Diabetes Res Care. 2019 Feb 7;7(1):e000613. doi: 10.1136/bmjdrc-2018-000613. eCollection 2019.
Results Reference
derived
PubMed Identifier
23060037
Citation
Thompson P, Roe DJ, Fales L, Buckmeier J, Wang F, Hamilton SR, Bhattacharyya A, Green S, Hsu CH, Chow HH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Martinez ME, Jacobs E, Ashbeck EL, Alberts DS, Lance P. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. Cancer Prev Res (Phila). 2012 Dec;5(12):1381-93. doi: 10.1158/1940-6207.CAPR-12-0204. Epub 2012 Oct 11.
Results Reference
derived
PubMed Identifier
18378608
Citation
Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E; Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008 Apr 22;117(16):2104-13. doi: 10.1161/CIRCULATIONAHA.108.764530. Epub 2008 Mar 31.
Results Reference
derived
Links:
URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272807/
Description
Journal Article

Learn more about this trial

Selenium for Prevention of Adenomatous Colorectal Polyps

We'll reach out to this number within 24 hrs